Method of treating cancer with IL-10 and antibodies that induce ADCC
First Claim
Patent Images
1. A method of treating cancer in a human subject, comprising administering to the subject:
- a) an antibody capable of inducing antibody-dependent cell-mediated cytotoxicity (ADCC), wherein the antibody is selected from the group consisting of cetuximab, trastuzumab, zalutumumab, matuzumab, rituximab, trastuzumab, ipilumumab, and nimotuzumab, andb) a therapeutically effective amount of an IL-10 agent, wherein the IL-10-agent is administered in an amount sufficient to maintain a mean IL-10 serum trough concentration of at least 1 ng/ml over a period of time of at least 1 week, wherein the mean IL-10 serum trough concentration is maintained for at least 90% of the period of time.
2 Assignments
0 Petitions
Accused Products
Abstract
Methods of treating subjects having a proliferative disease, disorder, or condition, including cancer, via the administration of an IL-10 agent, including pegylated IL-10, in combination with an antibody capable of inducing anti-body-dependent cell-mediated cytotoxicity, are provided.
-
Citations
18 Claims
-
1. A method of treating cancer in a human subject, comprising administering to the subject:
-
a) an antibody capable of inducing antibody-dependent cell-mediated cytotoxicity (ADCC), wherein the antibody is selected from the group consisting of cetuximab, trastuzumab, zalutumumab, matuzumab, rituximab, trastuzumab, ipilumumab, and nimotuzumab, and b) a therapeutically effective amount of an IL-10 agent, wherein the IL-10-agent is administered in an amount sufficient to maintain a mean IL-10 serum trough concentration of at least 1 ng/ml over a period of time of at least 1 week, wherein the mean IL-10 serum trough concentration is maintained for at least 90% of the period of time. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)
-
Specification